Condition: HEPATITIS B CHRONIC · Sponsor: Precision BioSciences, Inc.
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.
This description comes directly from the study's public registry record.
Precision Trial Manager · 800-371-8953 · ELIMINATE-B@precisionbiosciences.com
Always discuss trial participation with your own doctor first.
| Massachusetts General Hospital/Harvard University | Boston, Massachusetts, United States | Recruiting |
| Queen Mary Hospital, The University of Hong Kong | Hong Kong, Hong Kong, Hong Kong | Recruiting |
| ICS ARENSIA Exploratory Medicine SRL | Chisinau, Moldova | Recruiting |
| New Zealand Clinical Research | Auckland, New Zealand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06680232